Loading clinical trials...

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis | Clinical Trials | Clareo Health

NOT_YET_RECRUITING

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis

Prospective Cohort Study of Electrocautery Resection Combined With Hyperthermic Intrathoracic Chemotherapy for Thymic Epithelial Tumors With Pleural Metastasis

NCT07328074•Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

View on ClinicalTrials.gov

Summary

The goal of this observational study is to explore the effectiveness of electrocautery resection combined with hyperthermic intrathoracic chemotherapy (HITHOC) in patients with thymic epithelial tumors with pleural metastasis or recurrence. The study aims to: * Evaluate whether this combined treatment improves event-free survival in patients with pleural metastasis from thymic epithelial tumors * Assess the rates of grade ≥3 treatment-related adverse events * Examine how this treatment affects patients' quality of life Participants will: * Undergo extended thymectomy with electrocautery resection of pleural metastases * Receive two cycles of hyperthermic intrathoracic chemotherapy with cisplatin and doxorubicin at 42-43°C, 2-4 days apart * Complete quality of life questionnaires (EQ-5D) at baseline and regular intervals * Have regular follow-up visits with imaging and clinical assessments for up to 36 months to monitor for disease recurrence or progression

Eligibility

Age

16 - 80 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Pathologically confirmed thymic epithelial tumor (TET)
•Imaging evidence of thymic epithelial tumor with pleural dissemination or recurrence, deemed suitable for HITHOC by multidisciplinary thoracic team
•Age ≥16 years and ≤80 years
•American Society of Anesthesiologists (ASA) physical status classification I-II
•Normal major organ function
•No history of other malignancies
•Prior chemotherapy completed \>4 weeks, radiotherapy \>6 weeks, immunotherapy \>6 weeks before enrollment
•No allergy to cisplatin or doxorubicin
•Able to understand the study content and provide informed consent

Exclusion Criteria

•Evidence of extrathoracic metastasis on imaging or pathological examination
•Myasthenia gravis in unstable phase or acute exacerbation
•Severe systemic comorbidities, such as active infection, poorly controlled diabetes, coagulopathy, bleeding tendency, or ongoing thrombolytic/anticoagulation therapy
•Positive serum pregnancy test or lactation (females)
•History of organ transplantation (including autologous bone marrow transplantation and peripheral blood stem cell transplantation)
•History of peripheral nervous system disease, significant psychiatric disorder, or central nervous system disease
•Currently participating in other clinical trials

Locations (1)

Shanghai General Hospital, Department of Thoracic Surgery

Shanghai, Shanghai Municipality, China

Key Dates

Start Date

February 1, 2026

Primary Completion Date

February 1, 2031

Completion Date

February 1, 2031

Last Updated

February 5, 2026

Enrollment

ESTIMATED participants

Conditions

Thymic Epithelial TumorThymomaThymic CarcinomaPleural MetastasisPleural Recurrence

Interventions

Patients with thymic epithelial tumors with pleural metastasis or recurrence who undergo extended thymectomy with electrocautery resection of pleural metastases followed by two cycles of hyperthermic

PROCEDURE

Hyperthermic Intrathoracic Chemotherapy (HITHOC)

PROCEDURE

HEARTS Trial for Thoracic Cancers

NCT07132918

Non-Small Cell Lung Cancer (Stage III)Esophageal Cancer Stage I-III+3 more

View study

RECRUITINGPHASE2

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

NCT06838910

Thymic CarcinomaThymoma

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 5, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Electrocautery Resection Combined With HITHOC for Thymic Epithelial Tumors With Pleural Metastasis

Inclusion Criteria

Exclusion Criteria

HEARTS Trial for Thoracic Cancers

Tislelizumab Combined With Anlotinib as Second-line Therapy in Thymoma and Thymic Carcinoma

IMMUNORARE5: A National Platform of 5 Academic Phase II Trials Coordinated by Lyon University Hospital to Assess the Safety and the Efficacy of the IMMUNOtherapy With Domvanalimab + Zimberelimab Combination in Patients With Advanced RARE Cancers

PT-112 in Subjects With Thymoma and Thymic Carcinoma

Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer

Clinical Study of Postoperative Carbon Ion Radiotherapy for Thymus Tumor With Residual Tumor